6K:Initiation of Phase 2 Study for CM24 & dismissal of the BIRAD Lawsuit
false
פרפל ביוטק בע"מ
2
380
PURPLE BIOTECH LTD
Corporation no:
520031238
12724
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
18/05/2022
www.isa.gov.il
www.tase.co.il
Reference:
2022-02-060589
Time of broadcast:
15:33
15:33
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
6K:Initiation of Phase 2 Study for CM24 & dismissal of the BIRAD Lawsuit
ea160221-6k_purplebiotechEDGAR1_Bannerless_isa.pdf
6K: התחלת שלב 2 בCM24 ודחיית התביעה של BIRAD
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
27/04/2022
Address:
Oppenheimer, Science Park
4
,
Rehovot
7670104
,
Israel
Tel:
03-9333121
,
03-9311321
Fax:
03-5097196
E-mail address:
ir@purple-biotech.com
Company site:
www.kitovpharma.com
Previous names of reporting entity:
KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory:
Masas Ludmer Adi
Position of Signatory in the reporting corporation:
Company Controller
Name of Employer Company:
Address:
Menachem Begin Drive
132
,
Tel Aviv
6701101
Telephone:
03-9333121
Facsimile:
03-5097196
E-mail:
adim@kitovpharma.com
1
Israel